Humacyte, Inc. (HUMA)
| Market Cap | 155.41M -34.5% |
| Revenue (ttm) | 2.04M |
| Net Income | -40.83M |
| EPS | -0.26 |
| Shares Out | 222.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,241,515 |
| Open | 0.7083 |
| Previous Close | 0.7081 |
| Day's Range | 0.6900 - 0.7221 |
| 52-Week Range | 0.5469 - 2.9300 |
| Beta | 2.10 |
| Analysts | Strong Buy |
| Price Target | 6.19 (+784.29%) |
| Earnings Date | May 12, 2026 |
About HUMA
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would tar... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for HUMA stock is "Strong Buy." The 12-month stock price target is $6.19, which is an increase of 784.29% from the latest price.
News
Humacyte to Host Virtual KOL Event to Discuss ATEV for Arteriovenous (AV) Access for Hemodialysis Patients on April 28, 2026
DURHAM, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK and NEW ORLEANS, April 24, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care - - Positions Humacyte to advance discussions with corporate partners regarding international and indi...
Humacyte Appoints Jim Mercadante as Chief Commercial Officer
– Industry veteran with more than 25 years of experience will lead next phase of biotech company's commercial expansion – – Seasoned medtech commercial leader brings extensive field-specific success i...
Humacyte Announces Israeli Ministry of Health Acceptance of Marketing Authorization Application for Symvess® for Vascular Trauma Repair
- The Ministry of Health has set a 180-working-day review period for the MAA - - MAA process is one step in planned expansion of Symvess into multiple countries outside of the U.S - DURHAM, N.C., Apr...
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Humacyte Earnings Call Transcript: Q4 2025
Symvess saw expanding adoption in U.S. trauma centers and international markets, with strong clinical data and a favorable new price point driving higher VAC approvals and repeat usage. Financials improved year-over-year, and the pipeline advanced with key milestones expected in 2026.
Humacyte Announces Fourth Quarter and Year End 2025 Financial Results and Provides Business Update
- Total revenues from sales and research collaborations were $0.5 million for fourth quarter and $2.0 million for full year -
Humacyte Appoints Rick McElheny as Senior Vice President of Business Development
- Mr. McElheney brings more than 15 of years' experience in corporate development and alliance management at biopharma companies. - - He will work with the Company's leadership team to expand corpora...
Humacyte To Announce 2025 Fourth Quarter and Year End Financial Results and Provide Business Update on March 27, 2026
DURHAM, N.C., March 23, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results ...
Humacyte Submits Marketing Authorization Application for Symvess® in Israel for Vascular Trauma Repair
- Humacyte is also pursuing a mechanism for making Symvess available in Israel on a hospital-by-hospital basis in advance of MAA approval - - Preparation is underway for expansion of Symvess into oth...
Humacyte Transcript: Barclays 28th Annual Global Healthcare Conference
Launch of a first-in-class vascular product led to key learnings in hospital adoption, pricing, and education, with strong clinical evidence supporting trauma and dialysis indications. Expansion into dialysis and coronary markets is underway, with CMS engagement and Fresenius collaboration supporting growth.
Humacyte Transcript: TD Cowen 46th Annual Health Care Conference
A novel engineered vessel platform demonstrated strong clinical and economic value in trauma and dialysis, with FDA approval and market launch achieved. Ongoing trials target expanded indications, including a women-focused dialysis study and a CABG trial, with promising preclinical results and continued sales growth anticipated.
Humacyte To Participate in Upcoming Investor Conferences
DURHAM, N.C., March 02, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at com...
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
- Data presented at Annual Winter Meeting 2026 for the Vascular & Endovascular Surgery Society - - After up to 36 months of follow-up, extremity arterial trauma patients had high rates of limb salvag...
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Hospital Charge Data Showing High Expense of Preventable Extremity Arterial Injury Complications
- Data is from comprehensive review of hospital charges and all-payer claims over five years - - Preventable complications such as amputation and conduit infection increased initial hospital charges ...
Humacyte Announces Planned Marketing Authorization Application for Symvess® in Israel
- Expansion plans are based on requests for product access received from surgeons and hospitals in Israel - - Expansion of Symvess into other territories, including those in Europe and the Middle Eas...
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) - - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection,...
Humacyte Announces Credit Facility of Up to $77.5 Million with Avenue Capital
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels – ...
Humacyte Announces Six Presentations Scheduled for the Upcoming 52nd Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITHsymposium)
DURHAM, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at comm...
Humacyte Earnings Call Transcript: Q3 2025
Q3 2025 saw strong commercial momentum for Symvess, with sales rising to $703,000 and 92 hospitals eligible to purchase. Cost savings and a $56.5M capital raise extended cash runway beyond 12 months, while new clinical data and publications supported further adoption and pipeline progress.
Humacyte Announces Third Quarter 2025 Financial Results and Provides Business Update
- Total revenues of $753,000 for third quarter, and $1,571,000 for first nine months of 2025, from sales and collaborative research agreement - - Major advances in pipeline as Humacyte moves closer t...